New drug duo aims to fight back when standard treatments fail for advanced head & neck cancer
NCT ID NCT07388758
Summary
This study is testing whether a new combination of two immunotherapy drugs, scipibaimab and tislelizumab, can help control advanced nasopharyngeal cancer that has come back or spread after standard first-line treatments have stopped working. It will involve about 37 adults whose cancer progressed despite prior platinum-based chemotherapy and a PD-1 inhibitor drug. The main goal is to see if the combination can shrink tumors and is safe for patients who currently have limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.